Pharmacovigilance – News and Features
News
GSK and Theravance Announce Progression of LAMA/LABA Combination Treatment Into Phase III Development for COPD
Relovair™ programme expanded by start of large Phase IIIb COPD outcomes study.
News
Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial
Peregrine Pharmaceuticals, Inc., announces the completion of enrollment in the company's Phase Ib dose escalation safety study of bavituximab in patients coinfected with chronic hepatitis C virus (HCV) and HIV.
News
PharmaGap Provides Clinical Development Program Update
Through the first half of 2011, PharmaGap's clinical development program is focused on testing and development activities in order to provide the Company with the basis for selection of the initial cancer target for clinical trials.
News
Acurian: Maximizing Revenue through Better Patient Recruitment
Rick Malcolm from Acurian, a solution provider at the marcus evans Evolution Summit 2011, on accelerating patient recruitment in clinical trials.
News
Medpace Announces the Addition of Dan Weng, MD, PhD, MA as Vice President, ROW
Dr. Weng, an experienced clinical development professional, will be charged with driving global growth for Medpace in emerging markets.
News
Boston Scientific Completes Enrollment in EVOLVE Clinical Trial
Boston Scientific Corporation have announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent.
News
Hybrigenics Receives Green Light for its European Patent on High Therapeutic Doses of Inecalcitol
Hybrigenics, a bio-pharmaceutical group with a focus on research and development of new cancer treatments, today announces it has received from the European Patent Office the official notification of its intent to grant Hybrigenics’ patent on therapeutic uses of high doses of inecalcitol, under an accelerated procedure.
News
Peregrine Announces Initiation of Investigator-sponsored Trial in HER2-Negative Metastatic Breast Cancer
The Phase I trial will treat patients with Peregrine's monoclonal antibody bavituximab in combination with the chemotherapy agent paclitaxel.
News
4SC Announces First Patient Dosed in Phase I/II SHORE Study with Resminostat
The first patient dosed in the study with resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
News
YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial
YM BioSciences Inc., a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, have announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea.
Advertisement
